GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Antibiotice SA (BSE:ATB) » Definitions » LT-Debt-to-Total-Asset

Antibiotice (BSE:ATB) LT-Debt-to-Total-Asset : 0.03 (As of Dec. 2023)


View and export this data going back to 1997. Start your Free Trial

What is Antibiotice LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Antibiotice's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.03.

Antibiotice's long-term debt to total assets ratio declined from Dec. 2022 (0.05) to Dec. 2023 (0.03). It may suggest that Antibiotice is progressively becoming less dependent on debt to grow their business.


Antibiotice LT-Debt-to-Total-Asset Historical Data

The historical data trend for Antibiotice's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antibiotice LT-Debt-to-Total-Asset Chart

Antibiotice Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.07 0.08 0.06 0.05 0.03

Antibiotice Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.05 0.04 0.04 0.03

Antibiotice LT-Debt-to-Total-Asset Calculation

Antibiotice's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=36.75/1139.172
=0.03

Antibiotice's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )/Total Assets (Q: Dec. 2023 )
=36.75/1139.172
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Antibiotice  (BSE:ATB) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Antibiotice LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Antibiotice's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Antibiotice (BSE:ATB) Business Description

Traded in Other Exchanges
N/A
Address
1 Valea Lupului Street, Iasi, ROU, 707410
Antibiotice Ord is a Romania based company engaged in manufacturing generic medicines. It primarily develops and produces generic medicines for human use, veterinary medicines and active substance Nystatin. The group's generic medicines are primarily targeted at patients with infections, dermatological, cardiovascular, digestive tract diseases or diseases of the musculoskeletal system. It manufactures firm powders for solutions for injection and suspensions for injection (penicillins), capsules, tablets, suppositories and topical preparations (ointments, gels, creams).

Antibiotice (BSE:ATB) Headlines

No Headlines